Holding(s) in Company

RNS Number : 2317F
Hikma Pharmaceuticals Plc
10 November 2015
 



 

Notification of major interests in shares

 

LONDON, 10 November 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:

 

1

Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached

Hikma Pharmaceuticals PLC

 

 

 

2

Reason for the notification



An acquisition or disposal of voting rights

Yes


An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached

No


An event changing the breakdown of voting rights

No


Other (please specify): Compliance with the Transparency Directive

No

 

 

3

Full name of the person subject to the notification obligation

FMR LLC

4

Full name of shareholders

See Section 9

5

Date of the Transaction (and date on which the threshold crossed is reached differently)

5th November 2015

6

Date on which the issuer notified

6th November 2015

7

Threshold that is crossed

5%

8

Notified details

See A, B & C below




A. Voting rights attached to shares

Class type of shares (if possible using the ISIN code)

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of shares

Number of voting rights

Number of shares

Number of voting rights

% of voting rights

Direct

Indirect

Direct

Indirect

Direct

Indirect

Ordinary Shares (0.10 GBP)

GB00B0LCW083

9,936,267

9,936,267


9,973,414


9,973,414


5.00%

 

B. Qualifying Financial instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration Date

Exercise/Conversion Period/Date

Number of voting rights that may be acquired if the instrument if exercised/converted

% of voting rights

-

-

-

-

-

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise Price

Expiration Date

Exercise/Conversion Period/Date

Number of voting rights instrument refers to

% of voting rights

Nominal           

Delta

-

-

-

-

-

-

-

 

Total A+B+C

Number of Voting rights

% of voting rights

9,973,414

5.00

 

9

Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable


 

Custodian

Day to Day IM

Total

BANK OF NEW YORK BRUSSELS (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

6,040

BANK OF NEW YORK MELLON

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

116,750

BNP PARIBAS SEC SVCS LONDON

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

47,071

BROWN BROS HARRIMN LTD LUX (C)

FMRC-FMR CO., INC

486

BROWN BROTHERS HARRIMAN AND CO

FMRC-FMR CO., INC

65,914


FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED

44,975


PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

55,245


PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

537,558

CIBC MELLON TRUST (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

13,333

CITIBANK NA, HONG KONG BR (S)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

16,382

JP MORGAN, BOURNEMOUTH (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

9,809


PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

113,142

JPMORGAN CHASE BANK

FMRC-FMR CO., INC

4,089,565


FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED

151,087


PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

34,638


PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

58,643

MELLON BANK NA (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

259,991


PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

72,600

NATIONAL BANK TRUST (C)

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

14,829

NOMURA TRUST AND BANKING (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

553

NORTHERN TRUST CO (C)

FMRC-FMR CO., INC

200,615


FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED

2,598,333


PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

36,157


PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

272,510

STATE STREET BANK AND TR CO

FMRC-FMR CO., INC

303,042


PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

472,652


PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

381,494

Grand Total


9,973,414

 

Proxy Voting

10

Name of the proxy holder

FMR LLC

11

Number of voting rights proxy holder will acquire

37,147

12

Date on which proxy holder will acquire voting rights

5th November 2015

 

13

Additional Information


14

Contact name:

Peter Speirs, Company Secretary

15

Contact telephone number:

020 7399 2772

 

- ENDS -



About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million. 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLURSSRVUAAAAA
UK 100

Latest directors dealings